logo

Fate Therapeutics, Inc (FATE)



Trade FATE now with
  Date
  Headline
5/11/2018 1:52:31 PM Wedbush Is Cutting Fate Therapeutics, Inc (FATE) FY18 Estimate To -0.99 From -0.87
5/11/2018 1:52:15 PM Wedbush Is Lowering Fate Therapeutics, Inc (FATE) Q4 18 Estimate To -0.22 From -0.21
5/11/2018 1:51:54 PM Wedbush Is Cutting Fate Therapeutics, Inc (FATE) Q3 18 Estimate To -0.25 From -0.24
5/11/2018 1:51:43 PM Wedbush Is Cutting Fate Therapeutics, Inc (FATE) Q2 18 Estimate To -0.26 From -0.25
3/29/2018 2:34:15 PM Wedbush Reiterates Fate Therapeutics, Inc (FATE) At Outperform With $19 Price Target
3/29/2018 8:13:09 AM Fate Therapeutics Announces Initial Clinical Data Of FATE-NK100 For Recurrent Ovarian Cancer
3/19/2018 8:12:06 AM Fate Therapeutics Announces Addl Clinical Data From Phase 1 Stage Of PROTECT Trial Of ProTmune
3/6/2018 7:44:45 AM Wedbush Is Raising Fate Therapeutics, Inc (FATE) FY18 Rev. Estimate To 8.1 M From 4.1 M
3/6/2018 7:43:54 AM Wedbush Is Lowering Fate Therapeutics, Inc (FATE) FY18 Estimate To -0.87 From -0.84
3/6/2018 7:43:30 AM Wedbush Is Cutting Fate Therapeutics, Inc (FATE) Q4 18 Estimate To -0.21 From -0.18
3/6/2018 7:43:10 AM Wedbush Is Cutting Fate Therapeutics, Inc (FATE) Q3 18 Estimate To -0.24 From -0.22
3/6/2018 7:43:00 AM Wedbush Is Lowering Fate Therapeutics, Inc (FATE) Q2 18 Estimate To -0.25 From -0.22
3/6/2018 7:36:38 AM Wedbush Is Raising Fate Therapeutics, Inc (FATE) Q1 18 Estimate To -0.17 From -0.22
3/6/2018 7:31:21 AM Wedbush Reiterates Fate Therapeutics, Inc (FATE) At Outperform With $19 Up From $10 Price Target
1/18/2018 11:43:39 AM Wedbush Is Increasing Fate Therapeutics, Inc (FATE) FY18 Rev. Estimate To 141.6 M From 4.1 M
1/18/2018 11:43:16 AM Wedbush Is Increasing Fate Therapeutics, Inc (FATE) Q4 18 Rev. Estimate To 39.5 M From 1.0 M
1/18/2018 11:42:56 AM Wedbush Is Increasing Fate Therapeutics, Inc (FATE) Q3 18 Rev. Estimate To 37.0 M From 1.0 M
1/18/2018 11:42:39 AM Wedbush Is Increasing Fate Therapeutics, Inc (FATE) Q2 18 Rev. Estimate To 34.0 M From 1.0 M